{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:08:50Z","timestamp":1776834530425,"version":"3.51.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although ustekinumab (UST) has been recommended by guidelines as a parallel first-line biologic agent for Crohn\u2019s disease (CD), its efficacy varies among individuals. This study aimed to identify baseline clinical features and laboratory indicators that can predict clinical remission with UST to assist clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study collected data from patients with CD who received UST induction and maintenance therapy across multiple centers. The primary endpoint was the rate of clinical remission at week 48. Independent predictors of clinical remission were identified by multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves and the Youden index were used to determine optimal cutoff values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 157 included patients, clinical and endoscopic remission rates were 76.4% (120\/157) and 51.6% (81\/157), respectively. Multivariate analysis showed that baseline neutrophil count and baseline platelet\u2013lymphocyte ratio (PLR) were independent predictors of clinical remission at week 48 with UST treatment. Area under the ROC curve values for baseline neutrophil count, baseline PLR, and their combination were 0.633, 0.709, and 0.769, respectively. Optimal cutoff values for baseline neutrophil count and baseline PLR were \u22644.135\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L and &amp;lt;237.912, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Baseline neutrophil count and baseline PLR together constitute a simple and effective predictive model. This model may help identify patients who are more responsive to UST before treatment, offering a practical tool for individualized and precise treatment of CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1749683","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:34:46Z","timestamp":1776832486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutrophil count and platelet\u2013lymphocyte ratio as simple predictors of ustekinumab response in patients with Crohn\u2019s disease: a retrospective multicenter study"],"prefix":"10.3389","volume":"17","author":[{"given":"Lin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College","place":["Wuhu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Wuhu","place":["Wuhu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of the University of Science and Technology of China","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianxia","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongling Municipal Hospital","place":["Tongling, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengbing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Anqing Municipal Hospital","place":["Anqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingtao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Anqing Municipal Hospital","place":["Anqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongling Municipal Hospital","place":["Tongling, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of the University of Science and Technology of China","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Wuhu","place":["Wuhu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College","place":["Wuhu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"B2","article-title":"Crohn\u2019s disease: Diagnosis and management","volume":"98","author":"Veauthier","year":"2018","journal-title":"Am Fam Physician"},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3748\/wjg.v30.i1.50","article-title":"Treat to target in Crohn\u2019s disease: A practical guide for clinicians","volume":"30","author":"Srinivasan","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: A review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: The IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac011","article-title":"Ustekinumab in Crohn\u2019s disease: New data for positioning in treatment algorithm","volume":"16","author":"D\u2019Amico","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jcag\/gwaf001","article-title":"Assessing the role of ustekinumab dose escalation in Crohn\u2019s disease patients with loss of response: an observational study","volume":"8","author":"De Marco","year":"2025","journal-title":"J Can Assoc Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s479618","article-title":"Prediction of the short-term effectiveness of ustekinumab in patients with moderate to severe Crohn\u2019s disease","volume":"17","author":"Su","year":"2024","journal-title":"J Inflammation Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac030","article-title":"Utility of therapeutic drug monitoring for tumor necrosis factor antagonists and ustekinumab in postoperative Crohn\u2019s disease","volume":"28","author":"Pan","year":"2022","journal-title":"Inflammation Bowel Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07046-7","article-title":"Prior immunogenicity to anti-TNF biologics is not associated with increased anti-drug antibodies to vedolizumab or ustekinumab","volume":"67","author":"Costable","year":"2022","journal-title":"Dig Dis Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","article-title":"Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn\u2019s disease: a real-world multicenter Brazilian study","volume":"22","author":"Parra","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.389","article-title":"Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium","volume":"108","author":"Lazarev","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/978-3-030-15573-5_15","article-title":"Inflammatory bowel disease diagnosis and treatment of the consensus of opinion (Beijing), 2018","volume":"38","author":"Wu","year":"2018","journal-title":"Chin J Pract Internal Med"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/s0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [published correction appears in Lancet","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12715","article-title":"Neutrophil extracellular traps in pediatric inflammatory bowel disease","volume":"68","author":"Gottlieb","year":"2018","journal-title":"Pathol Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3526460","article-title":"Diagnostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Crohn\u2019s disease","volume":"2017","author":"Feng","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01796-4","article-title":"Nitric oxide, neutrophil\/lymphocyte, and platelet\/lymphocyte ratios as promising inflammatory biomarkers in complicated Crohn\u2019s disease: Outcomes of corticosteroids and anti-TNF-\u03b1 therapies","volume":"46","author":"Soufli","year":"2023","journal-title":"Inflammation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623899","article-title":"The predictive role of peripheral serum inflammatory markers NLR, PLR, and LMR in ulcerative colitis and Crohn\u2019s disease: a systematic review and meta-analysis","volume":"16","author":"Tan","year":"2025","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ans.17852","article-title":"Inflammatory markers may predict post-operative complications and recurrence in Crohn\u2019s disease patients undergoing gastrointestinal surgery","volume":"92","author":"Mullin","year":"2022","journal-title":"Anz J Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.957660","article-title":"Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management","volume":"13","author":"Ge","year":"2022","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/0002-9343(79)90633-8","article-title":"The role of neutrophils and neutrophil extracellular traps in vascular damage in systemic lupus erythematosus","volume":"8","author":"O\u2019Neil","year":"2019","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40577","article-title":"The role of neutrophil extracellular traps in Crohn\u2019s disease","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.21","article-title":"The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer","volume":"22","author":"Boone","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/cr.2010.150","article-title":"Neutrophil extracellular trap cell death requires both autophagy and superoxide generation","volume":"21","author":"Remijsen","year":"2011","journal-title":"Cell Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105779","article-title":"Neutrophil extracellular traps in inflammatory bowel diseases: Implications in pathogenesis and therapeutic targets","volume":"171","author":"Dos Santos Ramos","year":"2021","journal-title":"Pharmacol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13412","article-title":"Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease","volume":"100","author":"Chandwaskar","year":"2024","journal-title":"Scand J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2024.4101","article-title":"Deubiquitinase USP14 is upregulated in Crohn\u2019s disease and inhibits the NOD2 pathway mediated inflammatory response in vitro","volume":"68","author":"Li","year":"2024","journal-title":"Eur J Histochem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45070350","article-title":"Inflammation, autoinflammation and autoimmunity in inflammatory bowel diseases","volume":"45","author":"Padoan","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/ecco-jcc\/jjad119","article-title":"An intestinal Th17 subset is associated with inflammation in Crohn\u2019s disease and activated by adherent-invasive Escherichia coli","volume":"17","author":"Paroni","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169845","article-title":"Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitis","volume":"12","author":"Nishida","year":"2017","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1515\/jomb-2017-0050","article-title":"Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis","volume":"37","author":"Akpinar","year":"2018","journal-title":"J Med Biochem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao3089","article-title":"Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis","volume":"10","author":"Maugeri","year":"2018","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2025.118","article-title":"Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease","volume":"40","author":"Kim","year":"2025","journal-title":"Korean J Intern Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000520523","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as noninvasive predictors of the therapeutic outcomes of systemic corticosteroid therapy in ulcerative colitis","volume":"6","author":"Endo","year":"2021","journal-title":"Inflammation Intest Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmgh.2020.07.005","article-title":"Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn\u2019s disease","volume":"11","author":"Globig","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000548953","article-title":"New-onset ulcerative colitis after secukinumab initiation: A case report","volume":"19","author":"Hagh-Doust","year":"2025","journal-title":"Case Rep Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.37349\/edd.2025.1005103","article-title":"Ixekizumab-associated severe Crohn\u2019s in a patient without definitive immune-mediated inflammatory disease: case report and evidence-informed guidance for non-IBD clinicians","volume":"4","author":"Spiewak","year":"2025","journal-title":"Explor Dig Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001139856.66236.97","article-title":"Risk of De Novo inflammatory bowel disease in patients with psoriasis and psoriatic arthritis treated with IL-17A inhibitors: A population-based study","volume":"62","author":"Alsakarneh","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1322054","article-title":"Research progress of ustekinumab in the treatment of inflammatory bowel disease","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1749683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:34:57Z","timestamp":1776832497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1749683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2026.1749683"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1749683","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1749683"}}